Abstract
Hyperlipidemia is an important characteristic of nephrotic syndrome (NS). Elevation of plasma total cholesterol, or more specifically low-density lipoprotein cholesterol, is the major lipid abnormality in NS, although hypertriglyceridemia may develop as the disorder progresses. The pathophysiology of nephrotic hyperlipidemia is complex. The prevailing view is that both hepatic synthesis of lipids and of apolipoproteins is increased, and that the clearance of chylomicrons and very low-density lipoproteins is reduced. The precise contribution of increased lipogenesis and decreased lipid catabolism to hyperlipidemia, and their relationship to urinary protein loss, hypoalbuminemia and reduced serum oncotic pressure remain controversial. There are two potential risks of elevated plasma lipids: atherosclerosis and progression of glomerular injury. Although neither of these complications has been proved with certainty, there is growing evidence that both may be long-term consequences of NS. Therefore, the diagnosis and treatment of lipid abnormalities, important aspects of the management of nephrotic children, is summarized here to provide pediatric nephrologists with an informed choice.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Berlyne G, Mallick N (1969) Ischemic heart disease as a complication of nephrotic syndrome. Lancet II:399–400
Hopper J, Ryan P, Lee J, Rosenau W (1970) Lipoid nephrosis in 31 adult patients: renal biopsy study by light, electron and fluorescence microscopy with experience in treatment. Medicine (Baltimore) 49:321–341
Wass V, Jarrett R, Chilvers C, Cameron J (1979) Does the nephrotic syndrome increase the risk of cardiovascular disease? Lancet II:664–667
Pooling Project Research Group (1978) Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chron Dis 31:201–306
Martin M, Hulley S, Browner W, Kuller L, Wentworth D (1986) Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet II:934–936
Grundy SM, Vega GL (1989) Rational and management of hyperlipidemia of the nephrotic syndrome. Am J Med 87:3N-11N
Wheeler DC, Varghese Z, Moorhead JF (1989) Hyperlipidemia in nephrotic syndrome. Am J Nephrol 9:78–84
Strauss J, Zilleruelo G, Freundlich M, Abitbol C (1987) Less commonly recognized features of childhood nephrotic syndrome. Pediatr Clin North Am 34:591–607
Kaysen GA (1991) Hyperlipidemia of nephrotic syndrome. Kidney Int 39:S8-S15
Appel GB, Valeri A, Apple AS, Blum C (1989) The hyperlipidemia of nephrotic syndrome. Am J Med 87:45N-50N
Vlahcevic ZR, Heuman DM, Hylemon PB (1991) Regulation of bile acid synthesis. Hepatology 13:590–600
Dietschy JM (1990) LDL cholesterol: its regulation and manipulation. Hosp Pract [Off] 25:67–78
Baxter JH, Goodman HC, Havel RJ (1960) Serum lipids and lipoprotein alterations in nephrosis. J Clin Invest 39:455–464
McKenzie IFC, Nestel PJ (1968) Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome. J Clin Invest 47:1685–1695
Gherardi E, Rota E, Calandra S Genova R, Tamborino A (1977) Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome. Eur J Clin Invest 7:563–570
Ohta T, Matsuda I (1981) Lipid and apolipoprotein levels in patients with nephrotic syndrome. Clin Chim Acta 117: 133–143
DeMendoza S, Kashyap M, Chen C, Lutmer R (1976) High density lipoproteinuria in nephrotic syndrome. Metabolism 25:1143–1149
Oetliker O, Mordasini R, Lutschg J, Riesen W (1980) Lipoprotein metabolism in nephrotic syndrome in children. Pediatr Res 14:64–66
Chan M, Persaud J, Ramdial L, Varghese Z, Sweny P, Moorhead J (1981) Hyperlipidemia in untreated nephrotic syndrome, increased production or decreased removal? Clin Chim Acta 117:317–323
Cameron S, Wass V, Jarrett R, Chilvers C (1979) nephrotic syndrome and cardiovascular disease. Lancet II:1017–1019
Cohen L, Cramp D, Lewis A, Tikner T (1980) The mechanism of hyperlipidemia in the nephrotic syndrome: role of low albumin and the LCAT reaction. Clin Chim Acta 104:393–400
Sokolovskaya IV, Nikiforova NV (1984) High-density lipoprotein cholesterol in patients with untreated and treated nephrotic syndrome. Nephron 37:49–53
Zilleruelo G, Hsia S, Freundlich M, Gorman H, Strauss J (1984) Persistence of serum lipid abnormalities in children with idiopathic nephrotic syndrome. J Pediatr 104:61–64
Marsh J, Drabkin D (1960) Experimental reconstruction of metabolic pattern of lipid nephrosis: key role of hepatic protein synthesis in hyperlipidemia. Metabolism 9:946–955
Gherardi E, Calandra S (1980) Experimental nephrotic syndrome induced in the rat by puromycin aminonucleoside hepatic synthesis of neutral lipids and phospholipids from3H-water and3H-palmitate. Lipids 15:108–112
Golper TA, Feingold KR, Fulford MH, Siperstein MD (1986) The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat. J Lipid Res 27:1044–1051
Marsh JB, Drabkin DL (1958) Metabolic channeling in experimental nephrosis. V. Lipid metabolism in the early stages of the disease. J Biol Chem 230:1083–1091
Goldberg CARK, Helena CF, Oliveira ED, Quintao CR, McNamara DJ (1982) Increased hepatic cholesterol production due to liver hypertrophy in rat experimental nephrosis. Biochim Biophys Acta 710:71–75
Marsh JB, Drabkin DL (1955) Metabolic channeling in experimental nephrosis. II. Lipid metabolism. J Biol Chem 212:633–639
Thabet MA, Challa A, Chan JCM, Vlahcevic ZR, Pandak WM (1992) Mechanism of hypercholesterolemia in nephrotic syndrome (abstract). Pediatr Res 31:344A
Bernard DB (1988) Extrarenal complications of the nephrotic syndrome. Kidney Int 33:1184–1202
Kaysen G, Gambertoglio J, Felts J, Hutchison F (1987) Albumin synthesis, albuminuria and hyperlipidemia in nephrotic patients. Kidney Int 31: 1368–1376
Marsh J, Sparks C (1979) Hepatic secretion of lipoproteins in the rat and the effect of experimental nephrosis. J Clin Invest 64: 1229–1237
Radding C, Steinberg D (1960) Studies on the synthesis and secretion of serum lipoproteins by rat liver slices. J Clin Invest 39: 1560–1569
Baxter J, Goodman H, Allen J (1961) Effects of infusions of serum albumin on serum lipids and lipoproteins in nephrosis. J Clin Invest 40: 490–498
Marsh JB (1984) Lipoprotein metabolism in experimental nephrosis. J Lipid Res 25: 1619–1623
Golper TA, Schartz SH (1982) Impaired renal mevalonate metabolism in nephrotic syndrome: a stimulus for increased hepatic cholesterologensis independent of GFR and hypoalbuminemia. Metabolism 31: 471–476
Goldstein JL, Brown MS (1977) The low density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 46: 897–930
Garber DW, Gottlieb BA, Marsh JB, Sparks CE (1984) Catabolism of very low density lipoproteins in experimental nephrosis. J Clin Invest 74: 1375–1383
Chan M, Persaud J, Varghese Z, Moorhead J (1984) Post-heparin hepatic and lipoprotein lipasc activities in nephrotic syndrome. Aust NZJ Med 14: 841–847
Gutman A, Shafrir E (1963) Adipose tissue in experimental nephrotic syndrome. Am J Physiol 205: 702–706
Yamada M, Matsuda J (1970) Lipoprotein lipase in clinical and experimental nephrosis. Clin Chim Acta 30: 787–794
Calandra S, Gottardi E, Tarugi P (1983) Plasma postheparin lipolytic activity in rats with nephrotic syndrome. Horm Metab Res 15: 361–362
Rosenman RH, Byers OS (1960) Lipoprotein lipase metabolism in experimentally nephrotic rats. Proc Soc Exp Biol Med 103: 31–36
Furukawa S, Hirano T, Mamo JCL, Nagano S, Takahashi T (1990) Catabolic defect of triglyceride is associated with abnormal verylow-density lipoprotein in experimental nephrosis. Metabolism 39: 101–107
Davies RW, Staprans I, Hutchinson FN, Kaysen GA (1990) Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat. J Clin Invest 86: 600–605
Staprans I, Anderson CD, Lurz FW, Felts JM (1980) Separation of a lipoprotein lipase cofactor from the alpha-acid glycoprotein fraction from urine of nephrotic patients. Biochim Biophys Acta 617: 514–523
Jungst D, Caselmann WH, Kutschera P, Weisweiler P (1987) Relation of hyperlipemia in serum and loss of high density lipoproteins in urine in the nephrotic syndrome. Clin Chim Acta 168: 159–167
Appel GB, Blum, CB, Chien S, Kunis CL, Appel AS (1985) The hyperlipidemia of the nephrotic syndrome. N Engl J Med 312: 1544–1548
Ordonez JD, Hiatt R, Killebrrew E, Fireman B (1990) The risk of coronary artery disease among patients with the nephrotic syndrome (abstract). Kidney Int 37: 243A
Gilboa N (1976) Incidence of coronary heart disease associated with nephrotic syndrome. Med J Aust 1: 207–208
Alexander JH, Schapel GJ, Edwards KDG (1974) Increased incidence of coronary heart disease associated with combined elevation of serum triglycerides and cholesterol in the nephrotic syndrome in man. Med J Aust 2: 119–122
Moorhead JF (1991) Lipids and progressive kidney disease. Kidney Int 39: S35-S40
Keane WF, Kasiske BL, O'Donnell MP, Schmitz PG (1989) Therapeutic implications of lipid-lowering agents in the progression of renal disease. Am J Med 87: 21N-24N
Diamond JR (1989) Hyperlipidemia of nephrosis: pathophysiologic role in progressive glomerular disease. Am J Med 87: 25N-29N
Schmitz PG, Kariske BI, O'Donnell MP, Keane WF (1989) Lipids and progressive renal injury. Semin Nephrol 9: 354–369
Keane WF, Kasiske BL, O'Donnell MP (1988) Lipids and progressive glomerulosclerosis: a model analogous to atherosclerosis. Am J Nephrol 8: 261–271
Moorhead JF, El-Nahas M, Chan MK, Varghese Z (1982) Lipid nephrotoxicity in chronic glomerular and tubulo-interstitial disease. Lancet II: 1309–1311
Keane WF, Kasiske BL, O'Donnell JP (1988) Hyperlipidemia and the progression of renal disease. Am J Clin Nutr 47: 157–160
Klahr S, Schreiner G, Ichikawa I (1988) The progression of renal disease. N Engl J Med 318: 1657–1666
Diamond JR, Karnovsky MJ (1988) Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int 33: 917–924
Newmark SR, Anderson CF, Donadio JV (1975) Lipoprotein profile in adult nephrotics. Mayo Clin Proc 50: 359–364
Short CD, Danington PN, Malhick NP, Hunt LP, Tetlow L, Ishola M (1986) Serum and urinary high density lipoprotein in glomerular disease with proteinuria. Kidney Int 29: 1224–1228
Moorhead JF, Wheeler DC, Fernando R (1989) Injury to rat mesangial cells in culture by low density lipoproteins (abstract). Kidney Int 35: 433A
Kasiske BL, O'Donnell MP, Cleary MP (1988) Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33: 667–672
Harris KPG, Purkerson ML, Yates J (1989) Lowering cholesterol ameliorates renal disease in experimental nephrotic syndrome (abstract). Kidney Int 35: 429A
Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF (1988) Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62: 367–374
O'Donnell MP, Kasiske BL, Kim Y, Atluru D, Keane WF (1993) Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91: 83–87
Keane WF, Mulchahy WS, Kasiske BL, Kim Y, O'Donnell MP (1991) Hyperlipidemia and progressive renal disease. Kidney Int 39: S40-S47
Diamond JR (1991) Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis: roles of hypercholesterolemia and the glomerular macrophage. Kidney Int 39: S28-S33
Barcelli O (1991) Effect of dietary prostaglandin precursors on the progression of renal disease in animals. Kidney Int 39: S56-S63
Havel RJ (1989) Rationale for cholesterol lowering. Am J Med 87: 2–4
Brett AS (1989) Treating hypercholesterolemia. How should practicing physicians interpret the published data for patients? N Engl J Med 321: 676–679
D'Amico G, Gentile MG (1991) Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients. Kidney Int 39: S65-S69
Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langendorfer A, Keane WF (1990) The effects of lovastatin in hyperlipidemic patients with nephrotic syndrome. Am J Kidney Dis 15: 8–15
Coggins CH, Cornell BF (1988) Nutritional management of nephrotic syndrome. In: Mitch WE, Klahr S (eds) Nutrition and the kidney. Little Brown, Boston, pp 239–249
Grundy SM (1990) Management of hyperlipidemia of kidney disease. Kidney Int 37: 847–853
Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG (1980) Cholestyramine promotes receptor mediated low density lipoprotein catabolism. N Engl J Med 302: 1219–1222
Valeri A, Gelfand J, Blum C, Appel GB (1986) Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 8: 388–396
Rabelink AJ, Erkelens DW, Hene RJ, Joles JA, Koomans HA (1988) Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet II: 1335–1338
Kesaniemi YA, Grundy SM (1984) Influence of probucol on cholesterol and lipoprotein metabolism in man. J Lipid Res 25: 780–790
Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77: 641–644
Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320: 915–923
Iida H, Izumino K, Azaka M, Fujita M, Nishino A, Sasayama S (1987) Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. Nephron 47: 280–283
Bridgeman JF, Rosen SM, Thorp JM (1972) Complications during clofibrate treatment of nephrotic syndrome hyperlipoproteinemia. Lancet II: 506–509
Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319: 24–33
Kovanen PT, Bilheimer DW, Goldstein JL, Brown MS (1981) Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc Natl Acad Sci USA 78: 1194–1198
Vega GL, Grundy SM (1988) Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int 33: 1160–1168
Schaefer EJ, Levy RI (1985) Pathogenesis and management of lipoprotein disorders. N Engl J Med 312: 1300–1310
Olsson AG, Walldius G, Wahlberg G (1986) Pharmacological control of hyperlipidaemia: nicotinic acid and its analogues—mechanisms of action, effects, and clinical usage. In: Fears R, Prous JR (eds) Pharmacological control of hyperlipidaema. Science Publishers, Barcelona, pp 217–230
Grundy SM, Vega GL, Bilheimer DW (1985) Influence of combined therapy with mevinolin and interruption of bile-acid reasbsorption on low density lipoproteins in heterozygous familial hypercholesterolemia. Ann Intern Med 103: 339–343
Vega GL, Grundy SM (1987) Treatment of primary moderate hypercholesterolemia with lovastatin (Mevinolin) and colestipol. JAMA 257: 33–38
Keane WF, St Peter JV, Kasiske BL (1992) Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory? Kidney Int 38: S134-S141
Curry RC Jr, Roberts WC (1977) Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated. Am J Med 63: 183–192
Pandak WM, Vlahcevic ZR, Heuman DM, Hylemon PB (1990) Regulation of bile acid synthesis. V. Inhibition of conversion of 7-dehydrocholesterol to cholesterol is associated with down-regulation of cholesterol 7α-hydroxylase activity and inhibition of bile acid synthesis. J Lipid Res 31: 2149–2158
Bernard DB (1982) Metabolic abnormalities in nephrotic syndrome: pathophysiology and complications. In: Brenner BM, Stein JH (eds) Contemporary issues in nephrology. Churchill-Livingstone, New York, pp 85–120
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hassan Thabet, M.A.E., Salcedo, J.R. & Chan, J.C.M. Hyperlipidemia in childhood nephrotic syndrome. Pediatr Nephrol 7, 559–566 (1993). https://doi.org/10.1007/BF00852550
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00852550